Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Adjuvant immunotherapy with anti-CTLA-4 monoclonal antibody (ipilimumab) versus placebo after complete resection of high-risk Stage III melanoma: A randomized, doubleblind Phase 3 trial of the EORTC Melanoma Group

Next Previous
Trial Profile

Adjuvant immunotherapy with anti-CTLA-4 monoclonal antibody (ipilimumab) versus placebo after complete resection of high-risk Stage III melanoma: A randomized, doubleblind Phase 3 trial of the EORTC Melanoma Group

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Apr 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ipilimumab (Primary)
  • Indications Malignant melanoma
  • Focus Registrational; Therapeutic Use
  • Acronyms EORTC 18071
  • Sponsors Bristol-Myers Squibb

    • Most Recent Events

    • 01 Apr 2023 Results of post hoc pooled data from NCT00636168 and NCT02388906; assessing RFS and OS with nivolumab versus placebo and the numbers needed to treat (NNT) over 4 years, published in the Cancer Immunology Immunotherapy
    • 03 Dec 2021 Results of pooled analysis from (CheckMate-238 and EORTC 18071) assessing the impact of accounting for cured patients on the cost-effectiveness (CE) profile of nivolumab versus observation in adjuvant treatment of melanoma, presented at the 24th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
    • 15 Oct 2021 Results of pooled analysis of indirect treatment comparison (ITC) of adjuvant nivolumab versus placebo from CheckMate 238 and European Organisation for Research and Treatment of Cancer (EORTC) published in the European Journal of Cancer
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top